ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 29025596

RANK and EGFR in invasive breast carcinoma.

Papanastasiou AD and 5 others. Cancer Genet, 2017. Cited by 15 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. RANK and EGFR in invasive breast carcinoma. Papers, record 29025596. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29025596

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
RANK and EGFR in invasive breast carcinoma.
PubMed
Journal
Cancer Genet
PubMed
Year
2017
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
15
iCite
Relative citation ratio, by iCite
0.48
iCite
Revised in PubMed
2018-12-02
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Papanastasiou ADAnastasios D
2Sirinian CChaido
3Plakoula EEva
4Zolota VVassiliki
5Zarkadis IKIoannis K
6Kalofonos HPHaralabos P

Source PubMed

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
ErbB ReceptorsMajor topic
Receptor Activator of Nuclear Factor-kappa BMajor topic
Cell Line, Tumor
Female
Gene Expression Regulation, Neoplastic
Humans
Neoplasm Invasiveness
RNA, Messenger
Treatment Outcome

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by9

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.

PMIDTitleJournalYearIn PapersSource
39,558,045Mechanism of action of Salvia miltiorrhiza on avascular necrosis of the femoral head determined by integrated network pharmacology and molecular dynamics simulation.Sci Rep2024https://conductscience.org/library/papers/39558045PubMed
39,371,698Long-Term Survival in Human Epidermal Growth Factor Receptor 2-Positive Bone-Only Metastatic Breast Cancer: Trastuzumab, Denosumab, and Potential Synergistic Effects.Cureus2024https://conductscience.org/library/papers/39371698PubMed
38,533,261Potential pharmacological mechanisms of tanshinone IIA in the treatment of human neuroblastoma based on network pharmacological and molecular docking Technology.Front Pharmacol2024https://conductscience.org/library/papers/38533261PubMed
36,158,981Epidermal growth factor receptor (EGFR) expression in the serum of patients with triple-negative breast carcinoma: prognostic value of this biomarker.Ecancermedicalscience2022https://conductscience.org/library/papers/36158981PubMed
35,117,612Construction of differentially expressed Her-2 related lncRNA-mRNA-miRNA ceRNA network in Her-2 positive breast cancer.Transl Cancer Res2020https://conductscience.org/library/papers/35117612PubMed
31,796,128Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas.Breast Cancer Res2019https://conductscience.org/library/papers/31796128PubMed
31,382,135Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy.Transl Oncol2019https://conductscience.org/library/papers/31382135PubMed
31,052,546RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review.Int J Mol Sci2019https://conductscience.org/library/papers/31052546PubMed
30,621,730RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.J Exp Clin Cancer Res2019https://conductscience.org/library/papers/30621730PubMed

Genes9

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
EGF1,950PubTator's text mininghttps://conductscience.org/library/genes/1950NCBI Gene
EGFR1,956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
ERBB22,064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
ERBB32,065PubTator's text mininghttps://conductscience.org/library/genes/2065NCBI Gene
ERBB42,066PubTator's text mininghttps://conductscience.org/library/genes/2066NCBI Gene
MAPK15,594PubTator's text mininghttps://conductscience.org/library/genes/5594NCBI Gene
TNFRSF11A8,792PubTator's text mininghttps://conductscience.org/library/genes/8792NCBI Gene
TNFSF118,600PubTator's text mininghttps://conductscience.org/library/genes/8600NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29025596

GET https://conductscience.org/api/papers/v1/29025596/authors

API referenceFor AI assistants